Prevention of colitis-induced liver oxidative stress and inflammation in a transgenic mouse model with increased omega-3 polyunsaturated fatty acids

Rohwer, Nadine; Jelleschitz, Julia; Höhn, Annika; Weber, Daniela; Kühl, Anja A.; Wang, Chaoxuan; Ohno, Rei-ichi; Kampschulte, Nadja; Pietzner, Anne; Schebb, Nils Helge; Weylandt, Karsten H.; Grune, Tilman

doi:10.1016/j.redox.2023.102803

Cited by 6 publications

(3 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many clinical drugs, such as statins, metformin, thiazolidinediones and ω-3 fatty acids, have pleiotropic effects on LPL [ 39 ]. Moreover, metformin is thought to reduce the risk of IBDs or improve IBD risk [ 40 , 41 ], although no study has focused on the effect of these drugs on IBDs through the action of LPL. An observational study of 197 patients with IBD reported increased LPL expression in those patients [ 10 ], but that study included patients taking statins and steroids.…”

Section: Discussionmentioning

confidence: 99%

Correlations between genetically predicted lipid-lowering drug targets and inflammatory bowel disease

Huang,

Xiong

2024

Lipids Health Dis

View full text Add to dashboard Cite

Background Millions of individuals globally suffer from Inflammatory bowel diseases (IBDs). There is a dearth of large population-based investigations on lipid metabolism and IBDs, and it is unclear whether lipid-lowering drugs target IBDs causally. Consequently, the aim of this study was to investigate the effects of lipid-lowering medication targets on the occurrence and progression of IBDs. Methods Among the more than 400,000 participants in the UK Biobank cohort and the more than 170,000 participants in the Global Lipids Genetics Consortium, a total of nine genes linked to lipid-lowering drug targets were obtained (ABCG5/ABCG8, APOB, APOC3, LDLR, LPL, HMGCR, NPC1L1, PCSK9, and PPARA). IBD data were acquired from de Lange et al. (patients/sample size of IBDs: 25042/59957; ulcerative colitis (UC): 12366/45,975; Crohn's disease (CD): 12194/40,266) and the FinnGen cohort (patients/total sample size of IBDs: 4420/176,899; CD: 1520/171,906; UC: 3325/173,711). All four datasets were cross-combined for validation via Mendelian randomization analysis, and potential mediating factors were explored via mediation analysis. Results Genetically proxied APOC3 inhibition was related to increased IBD risk (odds ratio (95% confidence interval): 0.87 (0.80–0.95); P < 0.01) and UC risk (0.83 (0.73–0.94); P < 0.01). IBD and CD risk were reduced by genetic mimicry of LDLR and LPL enhancements, respectively (odds ratioLDLR: 1.18 (1.03–1.36); P = 0.018; odds ratioCD: 1.26 (1.11–1.43); P = 2.60E-04). Genetically proxied HMGCR inhibition was associated with increased CD risk (0.68 (0.50–0.94); P = 0.018). These findings were confirmed through Mendelian analysis of the cross-combination of four separate datasets. APOC3-mediated triglyceride levels may contribute to IBDs partly through mediated triglycerides, Clostridium sensu stricto 1, Clostridiaceae 1, or the Lachnospiraceae FCS020 group. LDLR enhancement may contribute to IBDs partly through increasing Lactobacillaceae. Conclusion Vigilance is required to prevent adverse effects on IBDs (UC) for patients receiving volanesorsen (an antisense oligonucleotide targeting ApoC3 mRNA) and adverse effects on CD for statin users. LPL and LDLR show promise as candidate drug targets for CD and IBD, respectively, with mechanisms that are potentially independent of their lipid-lowering effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Correlations between genetically predicted lipid-lowering drug targets and inflammatory bowel disease

Huang,

Xiong

2024

Lipids Health Dis

View full text Add to dashboard Cite

show abstract

“…Ingestion of EPA and DHA could significantly reduce the release of arachidonic acid (AA, which is involved in the pro-inflammatory response) from cell membrane phospholipids involved in inflammation, thereby inhibiting the inflammatory metabolic signaling pathways [ 220 ]. Specifically, EPA and DHA decrease the production of pro-inflammatory mediators such as prostaglandins-2, leukotrienes, hydroxyl eicosatetraenoic acid, and epoxy eicosatrienoic acid, which are produced by enzymes such as cyclooxygenase-2 (COX-2), lipoxygenase, or cytochrome P450, thereby inhibiting the inflammatory cascade.…”

Section: Marine Food Sources-derived Fatty Acid-based Nanomaterialsmentioning

confidence: 99%

Marine biomaterials in biomedical nano/micro-systems

Wang,

Chen,

Wang

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

Marine resources in unique marine environments provide abundant, cost-effective natural biomaterials with distinct structures, compositions, and biological activities compared to terrestrial species. These marine-derived raw materials, including polysaccharides, natural protein components, fatty acids, and marine minerals, etc., have shown great potential in preparing, stabilizing, or modifying multifunctional nano-/micro-systems and are widely applied in drug delivery, theragnostic, tissue engineering, etc. This review provides a comprehensive summary of the most current marine biomaterial-based nano-/micro-systems developed over the past three years, primarily focusing on therapeutic delivery studies and highlighting their potential to cure a variety of diseases. Specifically, we first provided a detailed introduction to the physicochemical characteristics and biological activities of natural marine biocomponents in their raw state. Furthermore, the assembly processes, potential functionalities of each building block, and a thorough evaluation of the pharmacokinetics and pharmacodynamics of advanced marine biomaterial-based systems and their effects on molecular pathophysiological processes were fully elucidated. Finally, a list of unresolved issues and pivotal challenges of marine-derived biomaterials applications, such as standardized distinction of raw materials, long-term biosafety in vivo, the feasibility of scale-up, etc., was presented. This review is expected to serve as a roadmap for fundamental research and facilitate the rational design of marine biomaterials for diverse emerging applications. Graphical Abstract

show abstract

“…Herbal medicinal plants have long been used as an alternative therapy to prevent and treat various diseases, including a wide range of acute and chronic gastrointestinal disorders [67][68][69][70][71][72]. In particular, the use of the Pistacia species has been covered extensively [5,47,[72][73][74][75]. Considering the three principal families of CMG chemical components, free fatty acids, terpenes, and phenolic compounds, literature data could support the beneficial effects of P. lentiscus on IBD.…”

Section: Inflammatory Bowel Diseasementioning

confidence: 99%

Chios Mastic Gum: Chemical Profile and Pharmacological Properties in Inflammatory Bowel Disease: From the Past to the Future

Ottria,

Xynomilakis,

Casati

et al. 2023

IJMS

View full text Add to dashboard Cite

Chios mastic gum, the product of the tree Pistacia lentiscus var. Chia, has been used for more than 2500 years in traditional Greek medicine for treating several diseases, thanks to the anti-inflammatory and antioxidant properties of its components. Despite the long-time use of mastic in gastroenterology and in particular in chronic-inflammation-associated diseases, to date, the literature lacks reviews regarding this topic. The aim of the present work is to summarize available data on the effects of P. lentiscus on inflammatory bowel disease. A comprehensive review of this topic could drive researchers to conduct future studies aimed at deeply investigating P. lentiscus effects and hypothesizing a mechanism of action. The present review, indeed, schematizes the possible bioactive components of mastic gum. Particular care is given to P. lentiscus var. Chia medicaments’ and supplements’ chemical compositions and their pharmacological action in inflammatory bowel disease.

show abstract

Prevention of colitis-induced liver oxidative stress and inflammation in a transgenic mouse model with increased omega-3 polyunsaturated fatty acids

Cited by 6 publications

References 64 publications

Correlations between genetically predicted lipid-lowering drug targets and inflammatory bowel disease

Correlations between genetically predicted lipid-lowering drug targets and inflammatory bowel disease

Marine biomaterials in biomedical nano/micro-systems

Chios Mastic Gum: Chemical Profile and Pharmacological Properties in Inflammatory Bowel Disease: From the Past to the Future

Contact Info

Product

Resources

About